Federico Leon
Family Medicine · Napa, CANPI 1659349173
Payments from drug & device makers
Across 78 payments — averaging $17.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$241
- Amgen$171
- E.r. Squibb & Sons, L.L.C.$159
- Teva Pharmaceuticals USA, Inc.$137
- GSK$67
- Novo Nordisk$66
- plus $553 from 16 others
What the payments were for
- Food & beverage$1,394100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 16 | $241 |
| Amgen | 8 | $171 |
| E.r. Squibb & Sons, L.L.C. | 3 | $159 |
| Teva Pharmaceuticals USA, Inc. | 9 | $137 |
| GSK | 4 | $67 |
| Novo Nordisk | 4 | $66 |
| AstraZeneca | 4 | $62 |
| Merck | 4 | $59 |
| Johnson & Johnson | 3 | $50 |
| Edwards Lifesciences | 2 | $48 |
| Pfizer | 3 | $42 |
| Astellas Pharma US Inc | 2 | $40 |
| AbbVie | 3 | $40 |
| Lilly USA, LLC | 2 | $38 |
| Sanofi Pasteur Inc. | 2 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $31 |
| Novartis | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Therapeuticsmd, Inc. | 1 | $14 |
| Sunovion Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELIQUIS$125
How this compares
$1,394 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 14 | $11,293 |
| BreynaBudesonide/Formoterol Fumarate | 12 | $2,316 |
| Gabapentin | 22 | $358 |
| Diclofenac Sodium | 12 | $269 |
| Levothyroxine Sodium | 14 | $132 |
| Lisinopril | 20 | $104 |
| Metformin Hcl | 29 | $102 |
| Triamcinolone Acetonide | 11 | $92 |
| Glimepiride | 27 | $82 |
| Atorvastatin Calcium | 16 | $60 |
| Amlodipine Besylate | 11 | $57 |
| Losartan Potassium | 13 | $34 |
| Fluoxetine Hcl | 14 | $22 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $241 | $11,29314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,533 family medicine providers in California.
Other family medicine in Napa
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.